For 4QFY2017, Aurobindo Pharma (APL) posted numbers which were lower than
expectations on sales, OPM & net profit fronts. On sales front, the company
posted sales of `3,582cr (v/s. `4,460cr expected) v/s. `3,674cr in 4QFY2016,
posting a yoy de-growth of 2.5%. On the operating front, the EBITDA margin
came in at 18.5% (v/s. 23.4% expected) v/s. 21.6% in 4QFY2016. Consequently,
the Adj. PAT came in at `532cr (v/s. `754cr expected) v/s. `555cr in 4QFY2016,
a yoy de-growth of 4.0%. We maintain our Buy rating on the stock, on the back
of attractive valuations.
Please Wait...
Please Wait...
Please Wait...
Please Wait...
Please Wait...
Please Wait...
Please Wait...
Please Wait...
Please Wait...
Please Wait...
Please Wait...
Please Wait...